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ABSTRACT
Objective: To investigate whether there is a difference
in the treatment effect of donepezil on cognition in
Alzheimer disease between industry-funded and
independent randomised controlled trials.
Design: Fixed effects meta-analysis of standardised
effects of donepezil on cognition as measured by the
Mini Mental State Examination and the Alzheimer’s
Disease Assessment Scale-cognitive subscale.
Data sources: Studies included in the meta-analyses
reported in the National Institute for Health and Care
Excellence (NICE) technical appraisal 217 updated with
new studies through a PubMed search.
Eligibility criteria: Inclusion criteria were double-
blind, placebo-controlled trials of any length comparing
patients diagnosed with probable Alzheimer disease
(according to the NINCDS-ADRDA/DSM-III/IV criteria)
taking any dosage of donepezil. Studies of combination
therapies (eg, donepezil and memantine) were excluded,
as were studies that enrolled patients with a diagnosis
of Alzheimer disease associated with other disorders
(eg, Parkinson’s disease and Down’s syndrome).
Results: Our search strategy identified 14 relevant
trials (4 independent) with suitable data. Trials
sponsored by pharmaceutical companies reported a
larger effect of donepezil on standardised cognitive tests
than trials published by independent research groups
(standardised mean difference (SMD)=0.46, 95% CI
0.37 to 0.55 vs SMD=0.33, 95% CI 0.18 to 0.48,
respectively). This difference remained when only data
representing change up to 12 weeks from baseline were
analysed (industry SMD=0.44, 95% CI 0.34 to 0.53 vs
independent SMD=0.35, 95% CI 0.18 to 0.52). Analysis
revealed that the effect of funding as a moderator
variable of study heterogeneity was not statistically
significant at either time point.
Conclusions: The effect size of donepezil on cognition
is larger in industry-funded than independent trials and
this is not explained by the longer duration of industry-
funded trials. The lack of a statistically significant
moderator effect may indicate that the differences are
due to chance, but may also result from lack of power.
INTRODUCTION
Dementia is of growing national importance,
and Alzheimer disease (AD) is the most
common cause. In spite of this, treatment for
AD is limited, and recent trials of new ther-
apies have yielded disappointing results.1 In
March 2011, the National Health Service’s
National Institute for Health and Care
Excellence (NICE) concluded that donepezil
hydrochloride (trade name Aricept, Pﬁzer)
could be ‘recommended as (an option) for
managing mild as well as moderate AD’.2
The conclusion was drawn despite reportedly
poor cost efﬁcacy3 and opinions that the use
of the drug is a ‘desperate measure’.4
The NICE decision was based on two
meta-analyses (the second was an update of
the ﬁrst) of randomised controlled trials
(RCTs) that demonstrated donepezil’s effect
on measures of cognition, behaviour, func-
tion and global skills.5 6 Of the 19 studies
included, 12 were produced by the compan-
ies that manufacture and market donepezil.
This is important because industry-sponsored
clinical trials are more likely to ﬁnd preferen-
tial outcomes for the industry’s product than
non-sponsored studies,7–9 demonstrating a
pervasive effect of ‘industry bias’.10 A failure
to address this potential bias in meta-analyses
increases the risk of inﬂating the drug’s true
efﬁcacy.11 12
While the different results published by
industry-funded and non-industry-funded
donepezil RCTs have been examined with
respect to language and rhetoric,13 the poten-
tial bias on funding sources has not been
examined by means of a formal meta-analysis.
Strengths and limitations of this study
▪ First study to review and demonstrate an object-
ive effect of industry funding on donepezil rando-
mised controlled trial outcome.
▪ Results are also controlled for different trial
lengths.
▪ Limited number of included trials.
▪ Evidence is limited to cognitive changes.
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Therefore, we performed a meta-analysis of all relevant
RCTs of donepezil in patients with mild-to-moderate AD,
stratifying by the source of funding.
METHOD
Study selection
We updated previous systematic reviews5 6 of RCTs using
a PubMed search strategy modiﬁed from that proposed
by Loveman et al6 in October 2012. Our search strategy
was amended to include any examples of donepezil’s
effect on neuropsychological tests (see online supple-
mentary appendix 1).
Eligibility criteria
We included double-blind, placebo-controlled RCTs of
any length comparing patients diagnosed with
mild-to-moderate probable AD (according to either
National Institute of Neurological and Communicative
Disorders and Stroke (NINCDS) and the Alzheimer’s
Disease and Related Disorders Association (ADRDA) or
Diagnostic and Statistical Manual of Mental Disorders
(DSM) III/IV criteria) taking any dosage of donepezil.
Studies were required to compare and report the
change from baseline on cognitive, behavioural, func-
tional or global assessments in the donepezil and
placebo groups. Studies that considered other separate
treatment arms in addition to the donepezil and
placebo groups were also included. RCTs that enrolled
patients with mixed dementias were included if AD was
the predominant dementia. Studies that assessed the
effect of donepezil in patients with AD in addition to
other non-dementia-related diseases as separate treat-
ment arms were also deemed suitable for inclusion.
Studies of combination therapies (eg, donepezil and
memantine) were excluded, as were studies that focused
exclusively on patients with a diagnosis of AD associated
with other disorders (eg, Parkinson’s disease and
Down’s syndrome).
Data collection
One author extracted data from included trials (LOJK).
Information was recorded on: study sponsor, sample size,
duration of the study, setting, characteristics of patients,
clinical diagnosis and cognitive assessment (mean
change from baseline). Relevant missing data were
requested from the corresponding authors. Only data for
changes on cognitive scales were collected due to limited
data detailing change in behaviour and function in inde-
pendent trials. Trials were deﬁned as ‘industry-funded’ if
any of the authors were employees of the sponsoring
pharmaceutical industry, or if the trial’s only source of
funding was from the sponsoring industry. Papers that
did not qualify for this deﬁnition were labelled as inde-
pendent of industry funding (or ‘independent’). Two
authors independently classiﬁed the included trials—
LOJK and TCR. Any disagreements were resolved by dis-
cussion or referred to a third author (SDS).
Assessing bias
Risk of bias in included trials was assessed using the rele-
vant Cochrane Collaboration’s tool.14 This tool assesses the
risk of bias across the domains of selection, performance,
detection, attrition and reporting. Trials are noted as
having a high, low or uncertain risk of bias for these spe-
ciﬁc domains. High or low risk is associated with reporting
inadequate or adequate methods of avoiding bias, respect-
ively. Uncertain risk is associated with partial or absent
reports for these methods. The risk of bias for trials
included in the two systematic reviews reported in the
NICE technical appraisal 217 was already assessed.6 7 The
risk of bias for new trials identiﬁed by the updated search
strategy was assessed by one author (LOJK). Publication
bias was assessed with a signiﬁcance test of funnel plot
asymmetry for effects reported at the study endpoint.
Planned analysis
Meta-analysis
We compared the standardised mean difference (SMD)
in cognitive scales (Mini Mental State Examination
(MMSE) and the Alzheimer’s Disease Assessment
Scale-cognitive subscale (ADAS-cog)) between the
placebo and donepezil groups in independent and
industry-funded trials at each study’s chosen endpoint.
The heterogeneity between trials was examined using
the I2 statistic, which indicates the proportion of the
total variation in the estimates that is due to between-
studies variation. I2 for the included trials varied
between 0% and 20%. Owing to this lack of heterogen-
eity, we considered it appropriate to pool independent
trials separately from industry-funded trials using ﬁxed
effects meta-analyses.
However, the effect of industry sponsorship may be
confounded by the duration of trials, as independent
trials are shorter and may not be able to observe the
relatively long-term effects of donepezil. To control for
this, we conducted a subgroup analysis comparing the
effect of donepezil and placebo up to and including
observations made at 12 weeks from baseline. We chose
this period as it was the point at which most data were
available for industry-funded and independent trials that
was also representative of the short-time frame of inde-
pendent trials and to accommodate the fact that, for
some trials, there were no data documenting change
prior to 12 weeks from baseline.
In order to investigate whether the overall heterogen-
eity of included trials was signiﬁcantly affected by the
presence of industry funding, we conducted an add-
itional ﬁxed effects model with funding as a moderator
variable for data from all time points and up to
12 weeks. To understand if the differences between the
independent and industry-funded effects were likely to
be statistically signiﬁcant, we investigated whether the
effect size of the independent trials fell within the 95%
CIs of the industry-funded effect.
All analyses were run using R V.2.15.215 with the
metafor package.16
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RESULTS
Search results
Figure 1 shows the selection process of trials included in
the current meta-analyses. A total of 14 trials (10
industry-funded and 4 independent) were deemed suit-
able for inclusion. A summary description of the 14
included trials is given in table 1. All trials made their
source of funding clear, with the exception of one
trial,17 the authors of which declared to be industry-
funded in a later publication.18
Risk of bias
Table 2 shows that none of the included trials were free
from biases. One important issue was a failure to report
how biases were (or were not) controlled. Where they
were reported, the trials had generally poor methodo-
logical quality. There was no clear difference in the risk
of bias between independent and industry-funded trials.
A test for funnel plot asymmetry returned a non-
signiﬁcant result (z=0.28, p=0.78), suggesting that publi-
cation bias did not have a substantial effect.
Figure 1 Flow chart of included
and excluded studies selected for
this meta-analysis. AD, Alzheimer
disease; RCT, randomised
controlled trial; NICE, National
Institute for Health and Care
Excellence.
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Meta-analyses
SMD at all time points
A total of 14 studies (4 independent) were included in this
analysis. The overall effect of donepezil on cognition was
statistically signiﬁcant (SMD=0.43, 95% CI 0.36 to 0.50,
p<0.0001), and independent and industry-funded studies
report donepezil as being signiﬁcantly more effective than
placebo (p<0.0001). The effect of donepezil on SMD in
cognitive scales was larger in industry-funded studies
(SMD=0.46, 95% CI 0.38 to 0.54) than in independent
studies (SMD=0.33, 95% CI 0.18 to 0.48; ﬁgure 2), giving a
difference of 0.13 (95% CI −0.1 to 0.36). Funding was not
found to be a statistically signiﬁcant moderator of study
heterogeneity (χ2 (1)=2.31, p=0.13).
Subgroup analysis: SMD at 12 weeks
Restricting the analysis to 10 studies (3 independent) that
assessed the effect of donepezil up to 12 weeks from base-
line did not affect the pattern of results reported above.
Data for ﬁve of these studies did not represent their
chosen endpoint.17 19–22 The overall effect of donepezil
is still statistically signiﬁcant (SMD=0.41, 95% CI 0.33 to
0.49, p<0.0001), and independent and industry-funded
studies report donepezil as being signiﬁcantly more
effective than placebo (p<0.0001). Industry-funded
studies still report a larger effect (SMD=0.44, 95% CI 0.34
to 0.53) compared with independent studies (SMD=0.34,
95% CI 0.19 to 0.50; ﬁgure 3), giving a difference of 0.1
(95% CI −0.15 to 0.35). As before, funding was not
found to be a statistically signiﬁcant moderator of study
heterogeneity (χ2 (1)=0.99, p=0.32).
DISCUSSION
Summary
Across included trials, the overall effect of donepezil on
cognition was statistically signiﬁcant. However, crucially,
the SMD change in cognitive scores between the
Table 1 Descriptions of the randomised controlled trials used in this meta-analysis
Study Measurement
Used
endpoints
(weeks) Donepezil (n) Placebo (n) Status Justification of definition
AD2000 (2004)3 MMSE 12 245 263 Independent No reported affiliation with
Pfizer
Greenberg et al34 ADAS-cog 6 51 52 Independent No conflict of interest
declared
Mazza et al35 MMSE 24 25 26 Independent No conflict of interest
declared
Winstein et al36 ADAS-cog 4 5 5 Independent Study supported in part by
Pfizer and Alzheimer’s
Disease Research Centre
Burns et al19 ADAS-cog 24 273 274 Industry-funded Author is an employee of
Pfizer Study is supported by
funds from Pfizer
Holmes et al37 MMSE 12 41 55 Industry-funded Authors are employees of
Pfizer
Homma et al17 ADAS-cog 24 126 113 Industry-funded No conflict of interest
declared, but authors
(E2020 Study Group) are
industry employees
Maher-Edwards et al38 ADAS-cog 24 65 56 Industry-funded* Authors are industry
employees
Mohs et al20 MMSE 54 207 208 Industry-funded Study supported by Pfizer.
Authors are employees of
Pfizer and Eisai
Rogers et al39 ADAS-cog 24 150 153 Industry-funded Authors are employees of
Pfizer
Rogers et al40 ADAS-cog 12 155 150 Industry-funded Authors are employees of
Pfizer
Seltzer et al41 ADAS-cog 24 91 55 Industry-funded Author is an employee of
Pfizer employee
Tune et al21 ADAS-cog 24 14 13 Industry-funded Authors are employees of
Pfizer
Winblad et al22 MMSE 52 135 137 Industry-funded Study supported by Pfizer
Independent studies are reported in grey rows.
*This is a GlaxoSmithKline study that investigates its own product in comparison to donepezil and placebo.
ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; MMSE, Mini Mental State Examination.
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donepezil and placebo groups was larger in trials sup-
ported by the pharmaceutical industry than that
observed in trials funded by independent organisations.
This pattern of results remained when we controlled for
study endpoint by only considering change up to
12 weeks from baseline. Analysis revealed that the effect
of funding as a moderator variable of study heterogen-
eity was not statistically signiﬁcant at either time point.
Strengths and limitations of the study
This report is the ﬁrst to stratify and analyse the effect of
donepezil according to funding source. It includes all
currently available published evidence regarding the
effect of donepezil. The analysis with data only up to
12 weeks demonstrates that the discrepancy reported
here is unlikely to be solely due to the longer duration
of industry-funded studies.
Our analyses revealed that there was no statistically sig-
niﬁcant effect of funding source on study heterogeneity.
This suggests that the different effects reported in inde-
pendent and industry-funded studies may be due to
chance. This possibility is also supported by the evidence
that the CIs of the difference contain zero. However, it is
important to note that a common pitfall of heterogeneity
analyses is that they lack the necessary power (ie, a sufﬁ-
cient number of studies) to reliably detect moderator
effects.23 24 This is likely to be an issue in the current
meta-analyses, as the samples included contain 10 or
fewer studies. This possibility is supported by a recent
review which simulated the power of moderator analyses
given the number of studies in a meta-analysis, the
number of participants in these studies and the expected
moderator effect size.25 With reference to their ﬁndings,
a meta-analysis of the current study’s size may not have
sufﬁcient power (0.8) to reliably detect a small-to-
medium moderator effect. It is also worth noting that the
level of α for these analyses should be increased to 0.10
to remedy these power issues.23 The difference we report
for the effect at all time points (ﬁgure 2) can be inter-
preted as being at near-signiﬁcance level (0.13).
Therefore, the lack of statistical signiﬁcance in hetero-
geneity may reﬂect the study’s lack of power to detect a
true small or medium moderator effect.
Independent studies could not be included in the
meta-analyses due to insufﬁcient data in the published
reports. Consequently, this lack of data could result in a less
robust independent treatment effect than that observed in
industry-funded studies. The dearth of data in conjunction
with the variability of study duration and cognitive scales
used restricted the number of possible controlled compari-
sons, and required the use of SMDs rather than clearly
comparing differences on a particular scale (eg, ADAS-cog
and MMSE). Finally, we were not able to assess differences
with respect to changes of behaviour, function or global
functioning since these outcomes were not reported sufﬁ-
ciently often to allow their inclusion in relevant
meta-analyses. These variables should not, however, be over-
looked, as these changes contribute towards the time to
institutionalisation, which in turn affects the cost-
effectiveness of donepezil.2 It would be useful to see if these
measures too are affected by the source of funding.
Ultimately, these limitations of available data and of
power are intrinsic to analysing reported (ie, published)
aggregated data. These same limitations could be over-
come with greater transparency of clinical data, or pos-
sibly through meta-analysing individual participant
data.26 Speciﬁcally, the authors argue that meta-analyses
of individuals’ data afford researchers with greater preci-
sion when estimating the effect of an intervention—or
what may moderate this effect—as there is more scope
in adjusting for confounding factors. Furthermore,
the authors also present a simulated example where the
Table 2 Relative risk of types of bias observed in randomised controlled trials reporting the effect of donepezil in
mild-to-moderate Alzheimer disease
Study
Selection bias
(sequence)
Selection bias
(allocation)
Performance
bias
Detection
bias
Attrition
bias
Reporting
bias
AD2000 (2004)3 − − − ? + +
Greenberg et al34 − − − − + −
Mazza et al35 ? + ? ? ? −
Winstein et al36 ? ? − − ? −
Burns et al19 ? ? ? ? + −
Holmes et al37 − − − ? + −
Homma et al17 ? ? ? ? + −
Maher-Edwards et al38 − − − − − +
Mohs et al20 ? ? ? − + ?
Rogers et al39 − ? ? ? + −
Rogers et al40 ? ? ? − + −
Seltzer et al41 − ? − − − +
Tune et al21 ? ? − − − −
Winblad et al22 − ? ? ? + −
Independent studies are reported in grey rows.
Risk is assessed as high (+), low (−) or uncertain (?). High or low risk is assigned when methods to avoid bias are inadequate or adequate,
respectively. Uncertain risk is assigned when methods to avoid bias are either partially reported or not reported.
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power of a meta-analysis used to detect moderator
effects on treatment is far greater when individual data
are used (90.8%) compared with when aggregated data
are used (14.8%). In the case of the latter meta-analysis,
this power indicates that there is an 85.2% chance of
failing to detect any moderator effect. This change to
the reporting of future studies would allow questions
like those of the current study to be assessed with
greater precision.
Other literature
This meta-analysis has provided a distinct example of the
established phenomenon that industry funding is
associated with a higher favourable outcome for the
industry’s product,7 as is the presence of an industry
employee among trials’ authors.9 While we cannot calcu-
late the chance of a favourable outcome given the com-
pany’s funding, the observation that such trials report
larger SMDs compared with independent trials implies
that a favourable outcome is more likely in industry-
funded trials.
With regard to the donepezil trials, the analyses com-
plement the more positive language and rhetoric (for
instance, frequent references to a drug’s effect as ‘sig-
niﬁcant’ outside of explicitly stated statistical signiﬁ-
cance) reported by industry papers for this drug as
Figure 2 Forest plot of
individual independent and
industry-funded studies’ reported
effect (standardised mean
difference) of donepezil compared
with placebo on cognitive scales
observed at study endpoint (95%
CIs).
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summarised by Gilstad and Finucane,13 suggesting that
the effect of donepezil in industry-funded papers is
qualitatively and quantitatively ampliﬁed. The same
authors argued that the effects reported by industry-
funded and independent trials were comparable.
However, they did not formally examine or calculate
effect size, but rather referred to the range of treatment
effect on particular scales.
The pattern of effects reported here has also been
observed in other meta-analyses that stratify by source of
funding. Speciﬁcally, the overall effect of donepezil
masking discrepant industry-funded and independent
effects mirrors a previous meta-analysis investigating
smoking as a risk factor for AD.12 While the overall
effect of smoking as a risk factor produced an incorrect
null result (ie, cigarette smoke was not a risk for devel-
oping AD), the overall protective effect of smoking in
tobacco in industry-funded trials cancelled out the
increased risk shown by non-tobacco industry trials.
While the results of the current study conﬁrm that done-
pezil is effective in terms of cognitive outcomes, it pro-
vides another instance of how a meta-analysis may
amalgamate conﬂicting evidence and produce an overall
inaccurate effect if funding sources are not considered.
Understanding this effect
The effect sizes—and the difference between them—
can be interpreted and understood as change in points
Figure 3 Forest plot of
individual independent and
industry-funded studies’ reported
effect (standardised mean
difference) of donepezil compared
with placebo on cognitive scales
observed up to 12 weeks from
baseline (95% CIs).
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on the MMSE. The industry-funded effect (0.46) was
similar to the effect size reported by Holmes et al, 2004
(0.45), which equates to a two-point improvement on
the MMSE. The independent effect (0.33), however, was
similar to the effect size reported by the AD2000 study
(0.30), which equates to a one-point improvement on
the MMSE. Although the ‘translations’ of these effects
are estimates, we can argue that the difference in SMDs
reported in the present analysis approximately equates
to a difference of one point on the MMSE.
We cannot conclude from these data whether the dif-
ference in the magnitude of treatment effect is due to
inﬂated effect estimates in the industry-funded trials or
to an underestimated effect in the independent trials;
nor can we deduce the reason for it. However, previous
literature has raised possibilities for this discrepancy that
may be applicable to donepezil trials.7 8
The ﬁrst is the use of data monitoring in trial manage-
ment. Data monitoring committees in trials are a
common interim safeguard against ineffective or poten-
tially dangerous treatments. However, the use of commit-
tees introduces the possibility of bias, either through post
hoc amendments to study design11 or by terminating
studies that show the drug to be ineffective at a prelimin-
ary stage, violating the uncertainty principle and equi-
poise of treatment efﬁcacy.27 28 Although there is no
evidence to suggest that monitoring is more prevalent in
industry studies than independent trials, a 2005 survey of
committees revealed that industry employees are also
members of the committees for their company’s trial.29
Therefore, it is likely that commercially unsuccessful
trials are terminated early. Second, the effects demon-
strated here may reﬂect different rates of publication bias
between independent and industry-funded trials. While
design bias entails publication bias, the latter alone
cannot explain examples of overwhelmingly positive evi-
dence from industry-sponsored trials.27 Therefore, it is
most likely that trials that are monitored and deemed
likely to succeed are in turn more likely to be published.
Furthermore, there was no evidence of publication bias
on examination of a funnel plot of included trials. Third,
there may be differences in patient populations across
trials. There were no obvious differences between the
groups of patients—in terms of scores on the MMSE or
from the Clinical Dementia Rating Scale. However, it
should be noted that the AD2000 trial is the only study to
explicitly report the inclusion of patients with vascular
dementia (for which donepezil is not licensed in the
UK), who comprised 18% of the donepezil group.3 All
other trials either explicitly stated exclusion of vascular
dementia or did not report the proportion of participants
with vascular dementias. Fourth, the discrepancy may be
due to the relative efﬁcacy of the placebo. However, while
variation in the placebo effect is well documented and
conceivable in trials,30 and although placebo treatments
are rarely described, it is unclear how patients in the
placebo group would systematically differ with respect to
study funding. Finally, it is possible that the differences
here are explained by the methodological quality of the
included trials. However, the risk of bias assessment for
individual trials suggests that industry-funded and inde-
pendent trials are as likely to show methodological short-
comings. This, in conjunction with previous research,
suggests that the quality of the included trials does not
differ based on funding. Speciﬁcally, a review of donepe-
zil trials indicates that they all in some way have methodo-
logical biases,31 despite a source of funding. The poor
quality of recent RCTs of donepezil was also raised in the
latest systematic review included in the NICE technical
appraisal 217.5
Implications
Ultimately, while the pharmaceutical industry’s inﬂuence
is ubiquitous and something ‘researchers cannot stop’,32
it can at least be identiﬁed before deciding whether
meta-analysed effects are as advertised. Our study sug-
gests that any effect of treatment that is included in a
meta-analysis should be stratiﬁed by a funding source. In
the absence of this practice, we should at least be cautious
in interpreting any reported effect of treatment from a
meta-analysis including (but not solely consisting of)
industry-funded trials. A possible way forward would be a
consistent protocol for reporting conﬂicts of interest that
is currently lacking at the level of systematic reviews and
meta-analyses,33 as well as of primary studies.32 The fre-
quency of poorly or partially reported methods obscures
the exact methodology used in these studies and high-
lights the need for a robust and agreed standard of
reporting. Future studies should strive to reduce meth-
odological differences between trials to ensure that any
effects of treatment are readily and more easily
comparable.
CONCLUSIONS
Based on the included data, the effect of donepezil com-
pared with placebo assessed by SMD change in cogni-
tion in AD is larger in industry-funded trials than in
independent trials. This is unlikely to be due to differ-
ences in trial duration. The lack of a statistically signiﬁ-
cant moderator effect may indicate that the differences
are due to chance, but may also result from lack of
power.
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